FeesSafety
Pluang+

TransCode to present Phase 1a trial results of cancer drug TTX-MC138 at ESMO 2026 in Madrid

Market News
19 Oct 2026, 15:04 WIB
PRNewsWire
View Source
Bullish
TransCode to present Phase 1a trial results of cancer drug TTX-MC138 at ESMO 2026 in Madrid

TransCode Therapeutics will present clinical data from its Phase 1a trial of TTX-MC138, a novel RNA-based cancer therapy targeting metastatic solid tumors, at the ESMO Congress 2026 in Madrid. The drug targets microRNA-10b, linked to cancer metastasis, and is currently advancing in clinical development including a Phase 2a trial. This presentation highlights progress in treating advanced cancers with innovative immuno-oncology approaches, signaling potential future treatment options for metastatic disease. The event runs from October 23-27, 2026, providing a platform for global oncology experts to review these findings.

TransCode Therapeutics' clinical trial update offers context for readers. For those tracking health-sector stocks, 68 of 150 US stocks rose and 54 fell on Pluang. Notable movers include Sanofi SA at USD 40.09 with a -1.28% change, Moderna at USD 215.33 down -1.23%, and Immunovant Inc. up 1.20% at USD 27.05, as of Oct 19, 2026 18:43 WIB.

More News

Alphabet and Meta Platforms show strong growth but face distinct risks and valuation differences for 2027.

Alphabet and Meta Platforms show strong growth but face distinct risks and valuation differences for 2027.

Alphabet and Meta Platforms both demonstrate robust revenue growth driven by digital advertising and AI integration, with Alphabet focusing on search and cloud services, and Meta on social media engagement. Alphabet reported $471.1 billion revenue an...

Market News
Bullish
18 minutes ago
Mastercard offers steady growth and stability over Coinbase's volatile crypto exposure for 2027 investments.

Mastercard offers steady growth and stability over Coinbase's volatile crypto exposure for 2027 investments.

Coinbase Global and Mastercard represent two paths in finance: crypto infrastructure versus traditional payments. Coinbase's revenue is tied to volatile crypto trading, showing a 26.6% revenue decline and a net loss of $701.6 million in the past year...

Market News
Neutral
31 minutes ago
Dec 9 key for markets: Fed rate decision, Broadcom earnings, Micron buybacks set to impact stocks.

Dec 9 key for markets: Fed rate decision, Broadcom earnings, Micron buybacks set to impact stocks.

On December 9, three major events will influence the stock market: the Federal Open Market Committee (FOMC) is expected to raise interest rates, Broadcom will report its earnings with a focus on AI semiconductor revenue, and Micron will begin a large...

Market News
Neutral
41 minutes ago
Rising rates challenge Realty Income but its strong dividend and diversification offer resilience.

Rising rates challenge Realty Income but its strong dividend and diversification offer resilience.

Realty Income, a large net-lease REIT with over 15,500 properties, faces headwinds from rising interest rates which increase borrowing costs and pressure profits. However, the company has a strong track record of increasing dividends for 32 years and...

Market News
Bullish
56 minutes ago
DICK'S Sporting Goods favored over Coupang for 2027 due to profitability and valuation despite Coupang's growth.

DICK'S Sporting Goods favored over Coupang for 2027 due to profitability and valuation despite Coupang's growth.

Coupang leads South Korea's e-commerce with strong logistics but faces losses and regulatory challenges, including a major data breach. DICK'S Sporting Goods, expanding through Foot Locker acquisition, shows strong profitability, a solid dividend, an...

Market News
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App